1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on July 27, 2024

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
GILD

Business Wire

a day ago

Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
GILD

Business Wire

a day ago

Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

3 Stocks That Can Help You to Get Richer in 2024 and Beyond
GILD

Motley Fool

2 days ago

3 Stocks That Can Help You to Get Richer in 2024 and Beyond

GILD

MT Newswires

2 days ago

Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
GILD

Business Wire

3 days ago

Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024

Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire
GILD

Benzinga

3 days ago

Invest $50K in CVS Health and Gilead Sciences to Become a Dividend Millionaire

ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial
GILD

Clinical Trials Arena

4 days ago

ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial

Nanotechnology in medicine: Who are the leading public companies?
GILD

Medical Device Network

4 days ago

Nanotechnology in medicine: Who are the leading public companies?

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
GILD

Zacks

4 days ago

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries
GILD

Pharmaceutical Technology

4 days ago

UNAIDS boss calls on Gilead to provide ‘miracle’ drug to developing countries

GILD

MT Newswires

4 days ago

Cantor Fitzgerald Adjusts Price Target on Gilead Sciences to $70 From $75

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
GILD

Business Wire

5 days ago

Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia

Gilead Sciences' (NASDAQ:GILD) one-year decline in earnings translates into losses for shareholders
GILD

Simply Wall St.

7 days ago

Gilead Sciences' (NASDAQ:GILD) one-year decline in earnings translates into losses for shareholders

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

8 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

GILD

MT Newswires

9 days ago

Gilead Sciences Chief Medical Officer Merdad Parsey to Leave

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
GILD

Business Wire

9 days ago

Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025

Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
GILD

Motley Fool

10 days ago

Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays

Gilead set to unveil data from HIV/AIDS trials
GILD

Clinical Trials Arena

10 days ago

Gilead set to unveil data from HIV/AIDS trials

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know
GILD

Zacks

10 days ago

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
GILD

Business Wire

10 days ago

Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024

GILD

MT Newswires

11 days ago

Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating

GILD

Morningstar Research

11 days ago

Analyst Report: Gilead Sciences, Inc.

3 Dividend Growth Stocks to Buy and Hold
GILD

Motley Fool

13 days ago

3 Dividend Growth Stocks to Buy and Hold

GILD

MT Newswires

15 days ago

Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78

Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?
GILD

Simply Wall St.

16 days ago

Is Gilead Sciences (NASDAQ:GILD) A Risky Investment?

Why Gilead Sciences (GILD) Outpaced the Stock Market Today
GILD

Zacks

16 days ago

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

GILD

MT Newswires

18 days ago

RBC Cuts Price Target on Gilead Sciences to $71 From $74, Keeps Sector Perform Rating

Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data
GILD

Investopedia

18 days ago

Gilead Gets Analyst Upgrade on 'Outstanding' HIV Treatment Data

Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?
GILD

Zacks

18 days ago

Gilead (GILD) Loses 17.6% YTD: How Should You Play the Stock?

GILD

MT Newswires

19 days ago

Raymond James Upgrades Gilead Sciences to Outperform From Market Perform, Price Target is $93

5 FDA decisions to watch in the third quarter
GILD

BioPharma Dive

24 days ago

5 FDA decisions to watch in the third quarter

Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?
GILD

Simply Wall St.

25 days ago

Should You Be Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE?

Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)
GILD

GuruFocus.com

25 days ago

Insider Sale: Chief Medical Officer Merdad Parsey Sells Shares of Gilead Sciences Inc (GILD)

Gilead Benefit Helps Employees Navigate Cancer Care
GILD

ACCESSWIRE

25 days ago

Gilead Benefit Helps Employees Navigate Cancer Care

Should You Hold Gilead Sciences (GILD)?
GILD

Insider Monkey

a month ago

Should You Hold Gilead Sciences (GILD)?

3 Magnificent Stocks Retirees Can Buy and Hold Forever
GILD

Motley Fool

a month ago

3 Magnificent Stocks Retirees Can Buy and Hold Forever

Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year
GILD

Simply Wall St.

a month ago

Recent uptick might appease Gilead Sciences, Inc. (NASDAQ:GILD) institutional owners after losing 4.6% over the past year

GILD

Argus Research

a month ago

Analyst Report: Gilead Sciences, Inc.

GILD

MT Newswires

a month ago

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117

GILD

Argus Research

a month ago

Market Digest: UAA, GILD, DINO, TRGP

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
GILD

Zacks

a month ago

Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know

The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine
GILD

Zacks

a month ago

The Zacks Analyst Blog Highlights Abbott Laboratories, BP, Gilead Sciences, Smith-Midland and Crimson Wine

GILD

MT Newswires

a month ago

Jefferies Adjusts Price Target on Gilead Sciences to $85 From $80

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock
GILD

Investor's Business Daily

a month ago

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock

US indexes open mixed, pharmaceutical stocks climb: Morning Brief
GILD

Yahoo Finance Video

a month ago

US indexes open mixed, pharmaceutical stocks climb: Morning Brief

Gilead sees encouraging results from shot to prevent HIV
GILD

Yahoo Finance Video

a month ago

Gilead sees encouraging results from shot to prevent HIV

Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection
GILD

Zacks

a month ago

Gilead (GILD) Up as Twice-Yearly HIV Shot Prevents Infection

5 Things to Know Before the Stock Market Opens
GILD

Investopedia

a month ago

5 Things to Know Before the Stock Market Opens

Nvidia loses spot as most valuable US company, triple-witching pressures market: Yahoo Finance
GILD

Yahoo Finance Video

a month ago

Nvidia loses spot as most valuable US company, triple-witching pressures market: Yahoo Finance

Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?
GILD

Zacks

a month ago

Strength Seen in Gilead (GILD): Can Its 8.5% Jump Turn into More Strength?

GILD

Investing.com

a month ago

CarMax, Gilead and Sarepta rise premarket; Nvidia falls

Housing trends, HPE CEO on Nvidia partnership: Market Domination
GILD

Yahoo Finance Video

a month ago

Housing trends, HPE CEO on Nvidia partnership: Market Domination

S&P 500 Gains and Losses Today: Index Dips After Briefly Crossing 5,500
GILD

Investopedia

a month ago

S&P 500 Gains and Losses Today: Index Dips After Briefly Crossing 5,500

Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.
GILD

Barrons.com

a month ago

Gilead’s Twice-Yearly Shot Prevents HIV. Where the Stock Is Headed.

Why Wall Street Is Chasing Ozempic Wannabes
GILD

The Wall Street Journal

a month ago

Why Wall Street Is Chasing Ozempic Wannabes

GILD

MT Newswires

a month ago

US Equities Markets Close Mixed Thursday as Markets Parse Latest Economic Data

Gilead Sciences stock jumps on HIV treatment trial success
GILD

Yahoo Finance Video

a month ago

Gilead Sciences stock jumps on HIV treatment trial success

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
GILD

Investor's Business Daily

a month ago

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective

GILD

MT Newswires

a month ago

Sector Update: Health Care Stocks Higher Late Afternoon

Gilead Stock Surges on Strong Results in HIV Drug Study
GILD

Investopedia

a month ago

Gilead Stock Surges on Strong Results in HIV Drug Study

Gilead Stock Gets Boost From HIV Drug Study Results
GILD

The Wall Street Journal

a month ago

Gilead Stock Gets Boost From HIV Drug Study Results

Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump
GILD

MT Newswires

a month ago

Gilead Sciences' Twice-Yearly Shot Prevents 100% of HIV Cases in Trial, Shares Jump

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
GILD

Business Wire

a month ago

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Gilead and Kite Pharma Celebrates Pride Month
GILD

ACCESSWIRE

a month ago

Gilead and Kite Pharma Celebrates Pride Month

Shareholders in Gilead Sciences (NASDAQ:GILD) are in the red if they invested a year ago
GILD

Simply Wall St.

a month ago

Shareholders in Gilead Sciences (NASDAQ:GILD) are in the red if they invested a year ago

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender
GILD

Investor's Business Daily

a month ago

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
GILD

Investor's Business Daily

a month ago

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.
GILD

Barrons.com

a month ago

Gilead Stock Gains. It’s Trying to Get Into the Obesity Drug Game.

Gilead Sciences Inc's Dividend Analysis
GILD

GuruFocus.com

a month ago

Gilead Sciences Inc's Dividend Analysis

GILD

MT Newswires

a month ago

Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
GILD

Business Wire

a month ago

New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
GILD

Zacks

a month ago

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

How Luciana Preger Is Helping Advance Gilead’s Work in Oncology
GILD

ACCESSWIRE

a month ago

How Luciana Preger Is Helping Advance Gilead’s Work in Oncology

3 Stocks With Mouthwatering Dividends You Can Buy Right Now
GILD

Motley Fool

2 months ago

3 Stocks With Mouthwatering Dividends You Can Buy Right Now

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
GILD

Zacks

2 months ago

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
GILD

Zacks

2 months ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

GILD

MT Newswires

2 months ago

Gilead Says Bulevirtide With PegIFN Data 'Superior' to Bulevirtide Monotherapy; Achieves 46% Rate of Undetectable HDV RNA

Gilead’s seladelpar shows promise in primary biliary cholangitis trial
GILD

Clinical Trials Arena

2 months ago

Gilead’s seladelpar shows promise in primary biliary cholangitis trial

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
GILD

Business Wire

2 months ago

Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA

Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?
GILD

Motley Fool

2 months ago

Should You Buy the 3 Highest-Yielding Dividend Stocks in the Nasdaq-100?

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis
GILD

ACCESSWIRE

2 months ago

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks
GILD

BioPharma Dive

2 months ago

Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks

Gilead progresses subject enrolment in HIV prevention trials
GILD

Clinical Trials Arena

2 months ago

Gilead progresses subject enrolment in HIV prevention trials

GILD

MT Newswires

2 months ago

Gilead Sciences Says Investigational Chronic Liver Disease Drug Shows 'Sustained Efficacy' in Long-Term Trial

J&J seeks expanded approvals for paediatric HIV-1 therapy
GILD

Pharmaceutical Technology

2 months ago

J&J seeks expanded approvals for paediatric HIV-1 therapy

Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
GILD

Business Wire

2 months ago

Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
GILD

Benzinga

2 months ago

National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection

GILD

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise Tuesday Afternoon

GILD

MT Newswires

2 months ago

Gilead Sciences Agrees to $40 Million Settlement of Federal TDF Lawsuit

The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
GILD

Zacks

2 months ago

The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR

Hedge Funds are Bullish on This Gene Therapy Stock
GILD

Insider Monkey

2 months ago

Hedge Funds are Bullish on This Gene Therapy Stock

Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
GILD

Zacks

2 months ago

Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study

Top Stock Reports for NextEra Energy, BP & Gilead Sciences
GILD

Zacks

2 months ago

Top Stock Reports for NextEra Energy, BP & Gilead Sciences

GILD

MT Newswires

2 months ago

Gilead Sciences Unit Says Tecartus Improves Overall Survival in Leukemia, Yescarta Well-Tolerated in Lymphoma

Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
GILD

Business Wire

2 months ago

Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
GILD

Business Wire

2 months ago

Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma

GILD

MT Newswires

2 months ago

Gilead Sciences, Arcus Biosciences's Colorectal Cancer Combination Therapy Shows Promise

GILD

Business Wire

2 months ago

Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer

GILD

Business Wire

2 months ago

Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal
GILD

Zacks

2 months ago

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

Share on Social Networks: